General Information of the Compound
Compound ID
CP0398508
Compound Name
VALSPODAR
    Show/Hide
Synonyms
Valspodar
    Show/Hide
Structure
Formula
C63H111N11O12
Molecular Weight
1214.646
Canonical SMILES
C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C
    Show/Hide
InChI
InChI=1S/C63H111N11O12/c1-26-27-28-41(16)53(76)52-57(80)67-49(38(10)11)61(84)68(19)33-48(75)69(20)44(29-34(2)3)56(79)66-50(39(12)13)62(85)70(21)45(30-35(4)5)55(78)64-42(17)54(77)65-43(18)58(81)71(22)46(31-36(6)7)59(82)72(23)47(32-37(8)9)60(83)73(24)51(40(14)15)63(86)74(52)25/h26-27,34-47,49-52H,28-33H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)(H,67,80)/b27-26+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52+/m1/s1
    Show/Hide
InChIKey
YJDYDFNKCBANTM-QCWCSKBGSA-N
CAS
121584-18-7
Physicochemical Property
logP
3.7232
Rotatable Bonds
15
Heavy Atom Count
86
Polar Areas
275.64
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
12
Complexity
86

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 5281884
SID: 12014683
ChEMBL ID
CHEMBL1086218
DrugBank ID
DB11869
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01546, ATP-dependent translocase ABCB1
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000034 Caco-2 Homo sapiens (Human)  1
1
IC50 = 110 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( Valspodar )
Drug Name Valspodar
Company Novartis
Indication
Acute myeloid leukaemia
Discontinued in Phase 3
Target(s)
Coagulation factor Xa (F10)
Inhibitor